Watchlist Price Alert

Kiniksa Pharmaceuticals L... (KNSA)

NASDAQ: KNSA · Real-Time Price · USD

27.81

0.16 (0.58%)

At close: May 05, 2025, 3:59 PM

27.85

0.14%

After-hours: May 05, 2025, 06:13 PM EDT

0.58% (1D)

Bid	26.78
Market Cap	2.03B
Revenue (ttm)	481.17M
Net Income (ttm)	-16.95M
EPS (ttm)	-0.6
PE Ratio (ttm)	-46.35
Forward PE	22.41
Analyst	Buy

Ask	29.19
Volume	494,529
Avg. Volume (20D)	673,611
Open	27.73
Previous Close	27.65
Day's Range	27.61 - 28.53
52-Week Range	17.38 - 28.56
Beta	0.31

About KNSA

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclo...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 25, 2018

Employees 315

Stock Exchange NASDAQ

Ticker Symbol KNSA

Website https://www.kiniksa.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for KNSA stock is "Buy." The 12-month stock price forecast is $40, which is an increase of 43.83% from the latest price.

Stock Forecasts

Earnings Surprise

Kiniksa Pharmaceuticals has released their quartely earnings on Apr 29, 2025:

Revenue of $137.78M exceeds estimates by $6.08M, with 72.54% YoY growth.

EPS of 0.11 misses estimates by -0.17, with 144.00% YoY growth.

Why Price Moved

6 days ago

+20.54%

Kiniksa Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription

6 months ago

-15.66%

Kiniksa Pharmaceuticals shares are trading lower after the company announced worse-than-expected Q3 financial results.

News

19 hours ago · seekingalpha.com

Kiniksa Pharmaceuticals: Making Steady Progress

Kiniksa Pharmaceuticals posted strong Q1 results last week, beating expectations and raising 2025 ARCALYST net sales guidance to $590-$605 million, up from $560-$580 million. Analyst firms are optimis...

6 days ago · seekingalpha.com

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q1 2025 Results Conference Call April 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman...

6 days ago · zacks.com

Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.02 per share.

3 weeks ago · zacks.com

Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Krystal Biotech, Inc. (KRYS) have performed compared to their sector so far this year.

1 month ago · zacks.com

Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know

The consensus price target hints at a 64.8% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

1 month ago · zacks.com

How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%

The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA). While the effectiveness of this highly sought-after metric is question...

1 month ago · fool.com

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable.

2 months ago · zacks.com

Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock

Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

2 months ago · zacks.com

Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be ...

2 months ago · zacks.com

Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?

The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

Load More News